Take the next step with Prolaris

Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.

Request information

Prolaris®
Prostate Cancer Prognostic Test

Personalizing prostate cancer treatment

Prolaris is a powerful tool that combines personalized information of tumor behavior with traditional clinical-pathological features to create the most prognostic information available. The Prolaris test offers unparalleled utility and unbiased insights to help you confidently recommend the best course of treatment for your patients.

Prolaris®
Prostate Cancer Prognostic Test

Personalizing prostate cancer treatment

Prolaris is a powerful tool that combines personalized information of tumor behavior with traditional clinical-pathological features to create the most prognostic information available. The Prolaris test offers unparalleled utility and unbiased insights to help you confidently recommend the best course of treatment for your patients.

Every man with prostate cancer deserves a better answer

Prolaris delivers a personalized risk assessment of a patient’s prostate cancer by combining clinically proven information with traditional diagnostic tools like PSA and Gleason.

Pathology offers a snapshot of how your patient’s cancer looks today, but it doesn’t give you the full picture. Prolaris combines traditional diagnostic tools like PSA, Gleason and tumor staging with an independent genomics score to tell — and show – what the cancer is doing, how it’s behaving, and potential outcomes from that behavior.

Risk assessment for any prostate cancer patient, at any stage

With Prolaris, you’ll save precious time and move your prostate cancer patients toward the right type of treatment from the beginning. Because the Prolaris test is done at the time of diagnosis and requires no additional biopsy, results can be available at your patient’s first cancer consult. Any untreated patient diagnosed with localized prostate cancer is a candidate for Prolaris testing.

With two clinically validated thresholds, Prolaris is:

  • The ONLY biomarker with an active surveillance threshold that was validated in untreated patients.
  • The ONLY test that can tell you which patients would have little to no benefit from ADT.1
plays 'Improving the patient experience through genomics' videolightbox

Improving the patient experience through genomics

Not all prostate cancer biomarkers tests are the same

When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. Prolaris is the only test studied in untreated patients and can identify the MOST patients for active surveillance across all biomarkers.2 For patients and providers looking to make confident prostate cancer treatment decisions, Prolaris:

Delivers industry-leading standard of care

Molecular tests like Prolaris are supported by NCCN guidelines as a 2A recommendation, which is considered standard of care. Prolaris is the only biomarker test on the market with both a validated Active Surveillance Threshold and Multi-Treatment Modality Threshold, giving both patients and providers confidence with their treatment decisions.

up to 65% change in treatment graphic

In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.4,5

62% increase in AS population graphic

Prolaris extends active surveillance candidate population by 62% compared to clinical and pathologic features alone.2

Prolaris is two times more prognostic than PSA/Gleason alone3


clinical variables graphic

Clarifies cancer risk and aggressiveness

Prolaris has an independent CCP score that determines cancer aggressiveness and is combined with more traditional clinical pathological features like PSA and Gleason to create the most prognostic test on the market.

Prolaris helps you pinpoint the right prostate cancer treatment plan

When it comes to treating prostate cancer, precision matters. So does quality of life. You want to ensure that your patients aren’t undertreated or overtreated. Prolaris can identify which men are safe for active surveillance and those who are not. With two clinically validated thresholds, Prolaris can also identify which patients should consider actively treating their cancer with one form of treatment, like surgery or radiation, and which patients will benefit from multiple forms of treatment.

Active surveillance

Men with prostate cancer that is not considered to be aggressive may be safely monitored using Active Surveillance. Active Surveillance is the recommended management option for most men with lower risk cancers.

Single-modal treatment

One form of treatment

Men with more aggressive tumors should undergo treatment. The type and intensity (magnitude) of the treatment is usually tailored to the potential risk of the disease. The most common forms of treatment include surgical removal of the prostate or radiation therapy.

Multi-modal therapy:

Two or more forms of treatment

Men with very aggressive cancer may be offered multi-modal therapy. Multi-modality therapy employs two or more therapies planned at the treatment onset. National cancer guidelines offer suggestions as to which may be a more appropriate treatment option based on the patient’s risk and potential outcomes of the treatment.

Providers recommend Prolaris for powerful cancer treatment insights.

plays 'The clinical utility of Prolaris in prostate cancer' videolightbox

The clinical utility of Prolaris in prostate cancer

Dr. Brian Richardson, urologist, discusses his experience using the Prolaris test to best treat his prostate cancer patients.

plays 'Prolaris empowers clinicians during a cancer consult' videolightbox

Prolaris empowers clinicians during a cancer consult

Learn more about how Prolaris can benefit a clinic and its patients.

How to test with Prolaris

Prolaris testing is simple and utilizes existing tissue from the diagnostic biopsy. No additional biopsies or blood draws are required. Myriad offers process experts to help customize ordering for your practice.

Basic vs streamlined ordering processBasic vs streamlined ordering process

Meet Myriad UroSuite

The complete suite of tests for a full prostate cancer workup.

Myriad UroSuite gives healthcare providers the ability to directly order a complete suite of tests – including biomarker, germline and somatic – for clear, comprehensive insights to guide prostate cancer treatment.

What to expect with every Prolaris test

Actionable

Every Prolaris test provides actionable results to inform more confident prostate cancer treatment decisions.

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.

Accurate

Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.

Prolaris resources

References:

  1. Tward JD, et al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose escalated radiation. International Journal of Radiation Oncology, Biology, Physics. 2021. DOI:https:// doi.org/10.1016/j.ijrobp.2021.09.034
  2. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.
  3. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095 -1099.
  4. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
  5. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618